FILTER
FILTERED INTERVIEW RESULTS
Marc Sale
CEO, FIRST CLASS METALS
"As we listed, we had credentials that other companies might take a year to aspire to."
Ilan Bahar
MANAGING DIRECTOR AND CO-HEAD, GLOBAL METALS & MINING, BMO CAPITAL MARKETS
BMO explains the current market for mine financing.
Keenan Jennings
VICE PRESIDENT, METALS EXPLORATION, BHP
BHP speaks to GBR about its exploration plans.
Lesley Warren
DIRECTOR, LASSONDE INSTITUTE OF MINING, UNIVERSITY OF TORONTO
"The mining community must recognize that resilience is going to come from reducing ESG risks, and that can only come from transformative innovation underpinned by research."
Hon. George Pirie
MINISTER OF MINES, GOVERNMENT OF ONTARIO
"The emphasis is on marrying the mineral potential of Northern Ontario with the industrial might of Southern Ontario."
Yves Rougerie
PRESIDENT & CEO, VISION LITHIUM
“The Québec government is very proactive in the lithium field, mainly in the industrial end use at this time, but we expect they will increase their support for the exploration and development phases in the coming years.”
Kevin Urbanski
CO-FOUNDER AND COO, RITHMIK SOLUTIONS
“I see the company having significantly more partners, all collaborating in optimizing the entire value chain through technology and AI.”
Rob McEwen & Michael Meding
EXECUTIVE CHAIRMAN & CHIEF OWNER (RM), VICE PRESIDENT & GENERAL MANAGER (MM), MCEWEN COPPER, MCEWEN MINING
"Los Azules is the ninth largest undeveloped copper deposit in the world, and within McEwen Mining, it represents the largest value and greatest excitement in our portfolio of assets."
Dean McPherson
HEAD, BUSINESS DEVELOPMENT - GLOBAL MINING, TORONTO STOCK EXCHANGE AND TSX VENTURE EXCHANGE
"We have a world class mining ecosystem built on the fact that Canada is a mining country."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
